Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

ABSTRACT: The evidence supporting the use of β-blockers in patients with acute coronary syndrome after successful percutaneous coronary intervention has been inconsistent and scarce. Between March 1, 2009, and December 30, 2014, a total of 3180 eligible patients with acute coronary syndrome undergoing percutaneous coronary intervention were consecutively enrolled. The primary end point was all-cause death and the secondary end point was a composite of all-cause death, nonfatal myocardial infarction, heart failure readmission, and cardiogenic hospitalization. Patients were compared according to the use of β-blockers at discharge. Compared with the no β-blocker group, the risk of all-cause death was significantly lower in the β-blocker group (hazard ratio [HR], 0.33; 95% CI, 0.17-0.65 [P=0.001]). A co

SUBMITTER: Li C 

PROVIDER: S-EPMC5210364 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature